Medicus Pharma Submits Orphan Drug Designation for SkinJect®
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Source: Newsfilter
- Orphan Drug Application: Medicus Pharma has submitted an Orphan Drug Designation application to the U.S. FDA for SkinJect® (D-MNA) targeting basal cell carcinoma in patients with Gorlin Syndrome, marking a strategic expansion into a high unmet need orphan indication that is expected to enhance market competitiveness.
- High-Burden Rare Disease: Gorlin Syndrome affects approximately 11,000 patients in the U.S., with individuals potentially developing dozens to over 1,000 basal cell carcinomas throughout their lives; current treatments rely heavily on surgery, lacking FDA-approved therapies, making SkinJect® a promising solution to alleviate both physical and psychological burdens on patients.
- Localized Treatment Advantages: SkinJect® is a dissolvable microneedle array designed for direct delivery of doxorubicin into tumor tissue, featuring high local concentration and minimal systemic exposure, which is particularly beneficial for managing multiple lesions in Gorlin Syndrome patients, potentially improving their treatment experience significantly.
- Clinical Research Progress: SkinJect® has demonstrated a favorable safety profile and evidence of clinical clearance in Phase 1 and Phase 2 studies for basal cell carcinoma; if granted orphan drug status, it will provide Medicus with 7 years of market exclusivity, enhancing its differentiated clinical and regulatory pathway.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDCX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDCX
Wall Street analysts forecast MDCX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.333
Low
12.00
Averages
12.00
High
12.00
Current: 0.333
Low
12.00
Averages
12.00
High
12.00
About MDCX
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. It is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. It has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medicus Pharma Submits IND Application for Teverelix Trial in UAE
- IND Application Submitted: Medicus Pharma has submitted an Investigational New Drug application to the Abu Dhabi Department of Health for the Phase 2a PRECISION-E2 trial, aimed at evaluating Teverelix for symptomatic endometriosis in women in the UAE, marking a significant advancement in the biotech sector.
- Clinical Trial Design: The PRECISION-E2 study will enroll approximately 84 participants and will utilize a randomized, placebo-controlled design to assess the pharmacodynamics, safety, and tolerability of Teverelix, providing crucial data for future Phase 2b development.
- Treatment Regimen Exploration: The trial will test three different administration regimens for Teverelix, including subcutaneous and intramuscular injections, aiming to identify the optimal dose and method for effective estradiol suppression while maintaining a favorable safety profile, which could significantly enhance patients' quality of life.
- Precision Medicine Strategy: Medicus Pharma is incorporating the Emirati Genome Program to analyze genomic and phenotypic factors affecting treatment response and disease biology, striving to develop a comprehensive precision medicine strategy for endometriosis patients, thereby driving innovation in this field.
See More
Medicus Pharma Submits IND Application for Teverelix®
- Clinical Trial Innovation: Medicus Pharma has submitted an IND application for Teverelix®, aiming to conduct the first genomics-enabled Phase 2a clinical trial in the UAE, which seeks to integrate clinical outcomes and genomic analyses to optimize treatment options, potentially offering more personalized care for millions of women.
- Participant Recruitment Plan: The trial is expected to enroll approximately 84 participants, leveraging data from the Emirati Genome Program to explore how genetic variations may influence hormonal therapy responses, which could provide critical data support for future precision medicine initiatives.
- Multiple Dosing Regimen Evaluation: The study will assess three Teverelix® dosing regimens, including subcutaneous and intramuscular administration, with the objective of identifying the optimal dose and route to achieve effective estradiol suppression while maintaining a favorable safety profile, potentially transforming current treatment paradigms.
- Potential in Women's Health: Successful completion of this trial could lay the groundwork for future Phase 2b development, potentially extending to other women's health indications such as uterine fibroids, further advancing the application of precision medicine in estrogen-driven diseases.
See More
Medicus Pharma Submits Clinical Trial Application for Teverelix®
- Successful Trial Application: Medicus Pharma has successfully submitted a substantial modification application for Teverelix® through the European Clinical Trials Information System, marking a significant milestone in advancing its prostate cancer treatment strategy and facilitating the drug's registration development.
- Focus on High-Risk Patients: The study aims to address advanced prostate cancer patients with elevated cardiovascular risk, as Medicus believes Teverelix®'s unique pharmacologic profile may offer significant therapeutic advantages, thereby filling a critical treatment gap in the market.
- Significant Market Opportunity: Medicus estimates that advanced prostate cancer patients with elevated cardiovascular risk represent an approximately $4 billion annual market opportunity across major pharmaceutical markets, and successfully developing such a therapy could yield substantial long-term commercial value for the company.
- Future Development Plans: The company intends to initiate patient enrollment later this year, with data from the Phase 2b study expected to inform dose selection and registrational study design, further enhancing interactions with regulatory authorities in both Europe and the United States.
See More
Medicus Pharma Secures $22 Million Financing Agreement
- Financing Agreement Secured: Medicus Pharma has entered into a $22 million financing agreement with an institutional investor, gaining $12 million in immediate operating capital, which is expected to significantly enhance the company's financial flexibility and operational capacity.
- Funding Structure Details: The financing includes a secured promissory note of $12.86 million at an 8.75% interest rate and another secured note of $10 million at a 5% interest rate with no original issue discount, which will help reduce overall financing costs.
- Cash Flow Projections: The company's cash is projected to increase to $30 million, with an operational cash runway expected to exceed 24 months, providing ample funding support for clinical development and potential business initiatives.
- Debt Repayment Strategy: Proceeds from the financing will be allocated to repay $2.5 million of outstanding debt while also supporting clinical development and general corporate operations, a strategy that aims to improve the company's financial health and drive future growth.
See More
Medicus Pharma Reports Q1 Financial Results
- Earnings Per Share Loss: Medicus Pharma reported a Q1 GAAP EPS of -$0.31, indicating ongoing challenges in profitability that may affect investor confidence moving forward.
- Cash Position Improvement: As of March 31, 2026, cash and cash equivalents stood at $6.4 million, up from $4.0 million in the same period of 2025, suggesting improved liquidity management within the company.
- Rising Operating Expenses: Operating expenses for Q1 reached $8.6 million, significantly higher than $5.1 million in Q1 2025, primarily driven by increases in general and administrative costs as well as R&D spending, which may pressure future profitability.
- Widening Net Loss: The company reported a net loss of $9.0 million for Q1, compared to a loss of $5.1 million in Q1 2025, reflecting ongoing financial strain and an increasingly competitive market environment.
See More
Medicus Pharma Reports Q1 2026 Financial Results and Corporate Update
- Clinical Advancements: In Q1 2026, Medicus Pharma continued to advance its clinical development of SkinJect® and Teverelix®, with the Phase 2 SKNJCT-003 study showing positive dose-response and registrational-grade clearance rates in the 200-µg treatment cohort, which is expected to facilitate FDA engagement for potential registration pathways.
- Financial Position: The company secured approximately $10 million through market financing in Q1, with cash and cash equivalents reaching $6.4 million, despite rising operating expenses of $8.6 million and a net loss of $9 million, indicating ongoing financial pressure.
- Strategic Collaborations: Medicus continues its collaboration with the Gorlin Syndrome Alliance to provide compassionate access to SkinJect® for Gorlin syndrome patients, further expanding market opportunities and enhancing brand influence.
- Future Outlook: The company anticipates a catalyst-rich 2026, planning an FDA Phase 2 meeting to define registration pathways and evaluating collaboration opportunities with HelixNano, reflecting a positive outlook for future growth.
See More
Medicus Pharma Submits IND Application for Teverelix Trial in UAE
- IND Application Submitted: Medicus Pharma has submitted an Investigational New Drug application to the Abu Dhabi Department of Health for the Phase 2a PRECISION-E2 trial, aimed at evaluating Teverelix for symptomatic endometriosis in women in the UAE, marking a significant advancement in the biotech sector.
- Clinical Trial Design: The PRECISION-E2 study will enroll approximately 84 participants and will utilize a randomized, placebo-controlled design to assess the pharmacodynamics, safety, and tolerability of Teverelix, providing crucial data for future Phase 2b development.
- Treatment Regimen Exploration: The trial will test three different administration regimens for Teverelix, including subcutaneous and intramuscular injections, aiming to identify the optimal dose and method for effective estradiol suppression while maintaining a favorable safety profile, which could significantly enhance patients' quality of life.
- Precision Medicine Strategy: Medicus Pharma is incorporating the Emirati Genome Program to analyze genomic and phenotypic factors affecting treatment response and disease biology, striving to develop a comprehensive precision medicine strategy for endometriosis patients, thereby driving innovation in this field.
See More
Medicus Pharma Submits IND Application for Teverelix®
- Clinical Trial Innovation: Medicus Pharma has submitted an IND application for Teverelix®, aiming to conduct the first genomics-enabled Phase 2a clinical trial in the UAE, which seeks to integrate clinical outcomes and genomic analyses to optimize treatment options, potentially offering more personalized care for millions of women.
- Participant Recruitment Plan: The trial is expected to enroll approximately 84 participants, leveraging data from the Emirati Genome Program to explore how genetic variations may influence hormonal therapy responses, which could provide critical data support for future precision medicine initiatives.
- Multiple Dosing Regimen Evaluation: The study will assess three Teverelix® dosing regimens, including subcutaneous and intramuscular administration, with the objective of identifying the optimal dose and route to achieve effective estradiol suppression while maintaining a favorable safety profile, potentially transforming current treatment paradigms.
- Potential in Women's Health: Successful completion of this trial could lay the groundwork for future Phase 2b development, potentially extending to other women's health indications such as uterine fibroids, further advancing the application of precision medicine in estrogen-driven diseases.
See More
Medicus Pharma Submits Clinical Trial Application for Teverelix®
- Successful Trial Application: Medicus Pharma has successfully submitted a substantial modification application for Teverelix® through the European Clinical Trials Information System, marking a significant milestone in advancing its prostate cancer treatment strategy and facilitating the drug's registration development.
- Focus on High-Risk Patients: The study aims to address advanced prostate cancer patients with elevated cardiovascular risk, as Medicus believes Teverelix®'s unique pharmacologic profile may offer significant therapeutic advantages, thereby filling a critical treatment gap in the market.
- Significant Market Opportunity: Medicus estimates that advanced prostate cancer patients with elevated cardiovascular risk represent an approximately $4 billion annual market opportunity across major pharmaceutical markets, and successfully developing such a therapy could yield substantial long-term commercial value for the company.
- Future Development Plans: The company intends to initiate patient enrollment later this year, with data from the Phase 2b study expected to inform dose selection and registrational study design, further enhancing interactions with regulatory authorities in both Europe and the United States.
See More
Medicus Pharma Secures $22 Million Financing Agreement
- Financing Agreement Secured: Medicus Pharma has entered into a $22 million financing agreement with an institutional investor, gaining $12 million in immediate operating capital, which is expected to significantly enhance the company's financial flexibility and operational capacity.
- Funding Structure Details: The financing includes a secured promissory note of $12.86 million at an 8.75% interest rate and another secured note of $10 million at a 5% interest rate with no original issue discount, which will help reduce overall financing costs.
- Cash Flow Projections: The company's cash is projected to increase to $30 million, with an operational cash runway expected to exceed 24 months, providing ample funding support for clinical development and potential business initiatives.
- Debt Repayment Strategy: Proceeds from the financing will be allocated to repay $2.5 million of outstanding debt while also supporting clinical development and general corporate operations, a strategy that aims to improve the company's financial health and drive future growth.
See More
Medicus Pharma Reports Q1 Financial Results
- Earnings Per Share Loss: Medicus Pharma reported a Q1 GAAP EPS of -$0.31, indicating ongoing challenges in profitability that may affect investor confidence moving forward.
- Cash Position Improvement: As of March 31, 2026, cash and cash equivalents stood at $6.4 million, up from $4.0 million in the same period of 2025, suggesting improved liquidity management within the company.
- Rising Operating Expenses: Operating expenses for Q1 reached $8.6 million, significantly higher than $5.1 million in Q1 2025, primarily driven by increases in general and administrative costs as well as R&D spending, which may pressure future profitability.
- Widening Net Loss: The company reported a net loss of $9.0 million for Q1, compared to a loss of $5.1 million in Q1 2025, reflecting ongoing financial strain and an increasingly competitive market environment.
See More
Medicus Pharma Reports Q1 2026 Financial Results and Corporate Update
- Clinical Advancements: In Q1 2026, Medicus Pharma continued to advance its clinical development of SkinJect® and Teverelix®, with the Phase 2 SKNJCT-003 study showing positive dose-response and registrational-grade clearance rates in the 200-µg treatment cohort, which is expected to facilitate FDA engagement for potential registration pathways.
- Financial Position: The company secured approximately $10 million through market financing in Q1, with cash and cash equivalents reaching $6.4 million, despite rising operating expenses of $8.6 million and a net loss of $9 million, indicating ongoing financial pressure.
- Strategic Collaborations: Medicus continues its collaboration with the Gorlin Syndrome Alliance to provide compassionate access to SkinJect® for Gorlin syndrome patients, further expanding market opportunities and enhancing brand influence.
- Future Outlook: The company anticipates a catalyst-rich 2026, planning an FDA Phase 2 meeting to define registration pathways and evaluating collaboration opportunities with HelixNano, reflecting a positive outlook for future growth.
See More
